Alzheimer’s disease biomarkers in cognitively normal adults

Takeaway

  • Early changes in cerebrospinal fluid (CSF) amyloid-β (Aβ) occur in preclinical Alzheimer’s disease (AD), with changes in neuronal injury and neurodegeneration markers possibly occurring closer in time to cognitive decline.

Why this matters

  • Multiple studies show evidence that the neuropathological course of AD is long and dynamic, with some changes occurring prior to clinical or cognitive symptom onset and some after; however, the sequence of these changes has not been explored in detail.

  • The incidence of AD is growing at a much faster rate versus available reliable treatments; therefore, a better understanding of the order of changes in AD may contribute to the development of specific therapeutic agents targeting different stages of the disease.

¿Quiere leer más?

Inicie sesión o regístrese para acceder a todo el contenido de Neurodiem.

¿Ya tiene una cuenta? Inicie sesión

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.